Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Venkata Viswanadh Edara, Carson Norwood, Katharine Floyd, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 516-521.e3
Open Access | Times Cited: 235

Showing 26-50 of 235 citing articles:

Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs
Meriem Bekliz, Kenneth Adea, Pauline Vetter, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 78
Immunity to SARS-CoV-2 up to 15 months after infection
Harold Marcotte, Antonio Piralla, Fanglei Zuo, et al.
iScience (2022) Vol. 25, Iss. 2, pp. 103743-103743
Open Access | Times Cited: 68
BCG vaccination stimulates integrated organ immunity by feedback of the adaptive immune response to imprint prolonged innate antiviral resistance
Audrey Lee, Katharine Floyd, Shengyang Wu, et al.
Nature Immunology (2023) Vol. 25, Iss. 1, pp. 41-53
Closed Access | Times Cited: 41
Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant
Venkata Viswanadh Edara, Lilin Lai, Malaya K. Sahoo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 99
SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination
Markus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 90
The success of SARS-CoV-2 vaccines and challenges ahead
Kanta Subbarao
Cell Host & Microbe (2021) Vol. 29, Iss. 7, pp. 1111-1123
Open Access | Times Cited: 87
In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion
Gilles Augusto, Mona O. Mohsen, Simon Zinkhan, et al.
Allergy (2021) Vol. 77, Iss. 1, pp. 111-117
Open Access | Times Cited: 82
mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status
Jason Neidleman, Xiaoyu Luo, Matthew McGregor, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 80
Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies
Maryam Noori, Seyed Aria Nejadghaderi, Shahnam Arshi, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 2
Open Access | Times Cited: 73
Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung
Matthew Gagné, Kizzmekia S. Corbett, Barbara J. Flynn, et al.
Cell (2021) Vol. 185, Iss. 1, pp. 113-130.e15
Open Access | Times Cited: 73
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective
Sarah Halawa, Soni Savai Pullamsetti, Charles R. M. Bangham, et al.
Nature Reviews Cardiology (2021) Vol. 19, Iss. 5, pp. 314-331
Open Access | Times Cited: 71
The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice
Wenqiang Sun, Lihong He, He Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 65
An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
Shiho Tanaka, Gard Nelson, C. Anders Olson, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 64
New variants of SARS-CoV-2
Rafael Cantón, Pilar Ramos, Alejandra García‐Botella, et al.
Revista Española de Quimioterapia (2021) Vol. 34, Iss. 5, pp. 419-428
Open Access | Times Cited: 63
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, et al.
Nature Immunology (2021) Vol. 22, Iss. 10, pp. 1306-1315
Open Access | Times Cited: 63
COVID‐19: vaccination problems
Harald Brüssow
Environmental Microbiology (2021) Vol. 23, Iss. 6, pp. 2878-2890
Open Access | Times Cited: 61
A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein
Nimisha Ghosh, Suman Nandi, Indrajit Saha
International Immunopharmacology (2022) Vol. 105, pp. 108565-108565
Open Access | Times Cited: 61
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
Hannah A. D. King, Michael Joyce, Inès Lakhal-Naouar, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 38
Open Access | Times Cited: 60
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
Kristen W. Cohen, Susanne L. Linderman, Zoe Moodie, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 58
Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses
Wanting He, Rami Musharrafieh, Ge Song, et al.
Nature Immunology (2022) Vol. 23, Iss. 6, pp. 960-970
Open Access | Times Cited: 56
The ins and outs of SARS-CoV-2 variants of concern (VOCs)
Mostafa Salehi‐Vaziri, Mehdi Fazlalipour, Seyed Mahmood Seyed Khorrami, et al.
Archives of Virology (2022) Vol. 167, Iss. 2, pp. 327-344
Open Access | Times Cited: 49
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
Matthew Gagné, Juan I. Moliva, Kathryn E. Foulds, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 47
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Deepta Bhattacharya
Immunity (2022) Vol. 55, Iss. 6, pp. 945-964
Open Access | Times Cited: 47
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial
Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
EClinicalMedicine (2022) Vol. 45, pp. 101323-101323
Open Access | Times Cited: 44
Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia
Anupriya Aggarwal, Alberto Ospina Stella, Gregory J. Walker, et al.
Nature Microbiology (2022) Vol. 7, Iss. 6, pp. 896-908
Open Access | Times Cited: 43

Scroll to top